Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effectiveness of Endocuff Vision in Improving ADR

ABSTRACT: The goal of distal attachment devices is to enhance an endoscopist’s adenoma detection rate (ADR). A device called EndoCuff Vision (ECV) has been introduced that employs a single row of flexible arms to evert colonic folds, thus optimizing mucosal visualization and enhancing ADR. ECV has been shown to be efficacious in improving ADR within the context of randomized trials. However, no ‘real-world’ studies have been published assessing the effectiveness of ECV in non-trial settings. The primary objective of this study is to assess the effect of ECV use on ADR in a routine screening-related population.

DISEASE(S): Colorectal Neoplasms

PROVIDER: 2339765 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Caenorhabditis elegans strain:N2, adr-1, adr-2, adr-1 adr-2

Project description:Caenorhabditis elegans strain:N2, adr-1, adr-2, adr-1 adr-2 Transcriptome or Gene expression

| PRJNA82293 | ENA

Expression data from MCF-7 and MCF-7/ADR cells

Project description:Chemoresistance in breast cancer has been a great interest in past studies, however, the development of rational therapeutic strategies targeting chemoresistant cells is still a challenge for clinical oncology.The resistant property of MCF7/ADR cells was confirmed by long term culture with Dox, cell viability, and PARP cleavage assays. Microarray analysis was performed to compare the global differences of gene expression between MCF-7 and MCF-7/ADR cells. MCF-7 and MCF-7/ADR gene expression profiles were analyzed. Total RNA were prepared for analysis with Affymetrix Human U133 Plus 2.0 arrays according to the manufacturerâs instructions.

2016-01-05 | E-GEOD-76540 | biostudies-arrayexpress

AVA-ADR-001- a small molecular inhibitor of ADAR1 (Immuno-oncology target)

Project description:To inhibitors for ADAR1 and a strong rationale for the development of ADAR1 p150 inhibitors for cancer immunotherapy Here, we describe AVA-ADR-001, a potential first-in-class small molecule inhibitor of ADAR1 p150 targeting the Z alpha domain. AVA-ADR-001 binds specifically to the Z alpha domain of ADAR1 p150 as confirmed by fluorescence spectroscopy and showed significant interferon induction in THP1 macrophages, which have high ADAR1 p150 expression compared with monocytes. Proteomics and transcriptomics analysis revealed significant upregulation of interferon signaling upon treatment with AVA-ADR -001. Interestingly, activation of interferon signaling resulted in AVA-ADR-001 induced cell killing in ADAR1-independent cell lines. In addition, treatment with AVA-ADR -001 resulted in significant activation of PKR, which may explain the decreased cell proliferation. Finally, AVA-ADR-001 showed superior anti-tumor efficacy compared to anti-PD1 in an in vivo tumor efficacy study and has a moderately synergistic effect when combined. Overall, this study reveals that ADAR1 p150 inhibition by AVA-ADR-001 exerts a multipronged impact on anti-tumor efficacy mediated by immune cells, accumulation of interferons and activation of PKR, resulting in protein translation inhibition and cell proliferation arrest.

2023-04-17 | GSE229503 | GEO

The dsRBP and inactive editor, ADR-1, utilizes dsRNA binding to regulate A-to-I RNA editing across the C. elegans transcriptome

Project description:Purpose: The purpose of this experiment is to expand the repertoire of C. elegans edited transcripts and identify the roles of ADR-1 as indirect regulator of editing and ADR-2 as the only active deaminase in vivo. Methods: Strand-specific RNA sequencing of wild-type and adr mutant worms, followed by a novel RNA variant calling and comparative analysis pipeline. Results: Despite lacking deaminase function, ADR-1 affects editing of over 60 adenosines within the 3’ UTRs of 16 different mRNAs. Furthermore, ADR-1 interacts directly with ADR-2 substrates, even in the absence of ADR-2; and mutations within its dsRNA binding domains abolished both binding and editing regulation. Conclusions: ADR-1 acts as a major regulator of editing by binding ADR-2 substrates in vivo and raises the possibility that other dsRNA binding proteins, including the inactive human ADARs, regulate RNA editing by deaminase-independent mechanisms. Strand-specific RNA sequencing of wild-type and adr mutant worms, followed by a novel RNA variant calling and comparative analysis pipeline.

2014-01-20 | E-GEOD-51556 | biostudies-arrayexpress

Expression data from MCF-7 and MCF-7/ADR cells

2016-01-05 | GSE76540 | GEO

Chryseobacterium oryzae strain:ADR-1

Project description:Chryseobacterium oryzae strain:ADR-1 Genome sequencing

| PRJNA820568 | ENA

The dsRBP and inactive editor, ADR-1, utilizes dsRNA binding to regulate A-to-I RNA editing across the C. elegans transcriptome

2014-01-20 | GSE51556 | GEO

RNA seq analysis of A2780 and A2780-ADR

Project description:We compared the global RNA expression level between doxorubicin-sensitive human ovarian cancer cell line A2780 and the adriamycin-resistant cell line A2780-ADR to elucidate the drug resistant related molecular mechanisms or targets.

2022-12-09 | GSE177038 | GEO

ADBP-1 regulates ADR-2 nuclear localization to control editing substrate selection

Project description:We generated RNA-seq libraries from three biological replicas of adbp-1 mutant worms at the embryo and L4 developmental stages. We wanted to identify editing sites globally in adbp-1 mutant worms and understand the preferable ADR-2 5’ and 3’ nearest neighbors of editing sites in wild-type worms in contrast to adbp-1 mutant worms. In addition, we wanted to test if the cytoplasmic localization of ADR-2 causes the downregulation of 3’UTR edited genes and lncRNAs, and test the effect of lacking ADBP-1 on global gene expression.

2024-07-03 | GSE230883 | GEO

ADR-directly-interfering amino acids based on competitive isoTOP-ABPP in normoxia

Project description:Hepatocellular carcinoma (HCC) is one of the most malignant tumors in the world with high morbidity and mortality rate. Many strategies have been tried to fight with HCC, yet effective treatment is still lacking. In this study, the in vitro and in vivo anti-HCC activity of andrographolide (ADR), an active ingredient of Andrographis Herba, has been demonstrated. We performed quantitative chemoproteomic profiling and identified heat shock protein HSP 90-alpha (HSP90AA1), an important molecular chaperone in endoplasmic reticulum protein processing, as the key target of ADR. The compound covalently bound to C597 and C598 therefore directly inhibited HSP90AA1 with isoform selectivity and reduced protein synthesis and triggered mitochondrial pathway-mediated apoptosis in HCC cancer cells collected in normoxia. Moreover, the inhibitory ability of ADR to HSP90AA1 was negatively correlated with the amount of this protein in cancer cells, and the mechanism was different from the existing inhibitors. Our study of ADR as a naturally derived and selective HSP90AA1 inhibitor provides new ideas for the treatment of HCC as well as other cancers.

2023-03-11 | PXD034583 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data